Detailed price information for Zenas Biopharma Inc (ZBIO-Q) from The Globe and Mail including charting and trades.
A major international Phase III clinical trial, led by Queen Mary University of London, has found that ocrelizumab—a medication already prescribed to some patients with MS—significantly slows ...
PERSEUS phase 3 study in primary progressive multiple sclerosis did not meet its primary endpoint in delaying time to onset of 6-month composite confirmed disability progression compared to placebo ...
BARCELONA, Spain — A new phase 3 trial of ocrelizumab in primary progressive multiple sclerosis (PPMS) showed meaningful benefit in older patients and those with advanced disease — a first for this ...
In people with primary progressive multiple sclerosis (PPMS), depressive symptoms measured using the Hospital Anxiety and Depression Scale (HADS) predicted subsequent neurologic disability progression ...
I was diagnosed with relapsing-remitting multiple sclerosis (RRMS) at the age of 46.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results